SLC5A2 and heart failure: Additionally, the EMPEROR-preserved and DELIVER studies documented 16-20% reductions in heart failure hospitalizations in patients with preserved ejection fraction treated with SGLT2 inhibitors, suggesting significant benefits even in patients without severe ventricular dysfunction [21-25].